Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Nov 5, 2019
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a person's genetic makeup affects their response to medications, specifically looking at cases where patients have experienced unwanted side effects or where treatments have not worked as expected. The goal is to collect information from these cases to better understand how genetic testing can help identify why some people have problems with certain drugs. This information will be used to create a standard procedure for using genetic testing in community pharmacies, which could lead to safer and more effective medication use for everyone.
To participate in the trial, you should be between the ages of 65 and 74 and have either started a new medication that may have a known genetic link or have experienced side effects or treatment failures with your current medications that could also be connected to your genetics. You will need to provide consent to join, and you should be comfortable visiting the study pharmacy in person. If you join, you can expect to share your experiences with medications, and in return, help contribute to improving future medication safety and effectiveness for others.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • New medication with known PGx association (preemptive)
- • Current medication with observation of adverse drug reactions probably linked to drugs with known PGx association (reactive)
- • Current medication with observation of therapy failure probably linked to drugs with known PGx association (reactive)
- • Current and/or new medication and a family history of adverse drug reactions/therapy failure probably linked to drugs with known PGx association
- • Signed informed consent; for patients \< 14 years, the legal representative needs to sign the informed consent
- Exclusion Criteria:
- • Insufficient German knowledge
- • Not able to personally visit to the study pharmacy
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Kurt Hersberger, Prof. Dr.
Study Chair
Pharmaceutical Care Research Group; Department of Pharmaceutical Sciences, University Basel
Samuel Allemann, Prof. Dr.
Principal Investigator
Pharmaceutical Care Research Group; Department of Pharmaceutical Sciences, University Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials